title: Subcutaneous administration of bortezomib: strategies to reduce injection site reactions.
abstract: Bortezomib (Velcade) is approved by the FDA for IV or SC injection in select patients with multiple myeloma or mantle cell lymphoma. The SC route functions as an alternative to IV administration for patients with poor IV access. Learn about effective strategies used to reduce injection site reactions that can occur with SC delivery.
authors.affiliation: University of Arizona Cancer Center, Tucson, Arizona; Northwestern Medical Faculty Foundation, Chicago, Illinois; and University of Maryland Medical System, Baltimore, Maryland.
authors.forename: Sandra
authors.initials: S
authors.lastname: Kurtin
authors.affiliation: University of Arizona Cancer Center, Tucson, Arizona; Northwestern Medical Faculty Foundation, Chicago, Illinois; and University of Maryland Medical System, Baltimore, Maryland.
authors.forename: Carol S
authors.initials: CS
authors.lastname: Knop
authors.affiliation: University of Arizona Cancer Center, Tucson, Arizona; Northwestern Medical Faculty Foundation, Chicago, Illinois; and University of Maryland Medical System, Baltimore, Maryland.
authors.forename: Todd
authors.initials: T
authors.lastname: Milliron